Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

NCT02051335 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Memory Impairment
Alzheimer's Disease

Interventions

DRUG: Roflumilast
DRUG: Roflumilast placebo
DRUG: Donepezil
DRUG: Donepezil placebo
DRUG: Scopolamine

Sponsor

AstraZeneca